In the high-stakes world of radiopharmaceuticals, the industry is just beginning to realize the full potential of this targeted therapy modality. A surge of capital flowing into the field is signalling not only robust investment, but a shared urgency to strengthen supply pipelines and scale clinical manufacturing capacity.